

Dear investors and analysts,

Thank you for your continued attention and trust placed in Viva Biotech. In the coming new year, Viva Biotech will remain committed to our mission of becoming a cradle for innovative biotechnology companies around the world and keep moving forward with your company and support. At this joyous holiday season, we wish you and your family health, happiness and all the best!

IR Team of Viva Biotech



Company News

Viva Biotech Successfully Held 2020 Online Investor Day



On December 8, 2020, Viva Biotech 2020 Online Investor Day was successfully held. The management team of Viva Biotech and the new board of directors of Langhua Pharmaceutical participated collectively. The management team conducted an online dialogue with nearly 400 investors, focusing on the company's strategy, personnel plans, technology platforms, integration strategic plans, investment incubation, and more.

[\(More details\)](#)

Viva Biotech and AlphaMa Reached Cooperation Agreement on IntelligentDEL

On December 21, 2020, Viva Biotech signed a new drug discovery technology cooperation agreement with AlphaMa Biotech Co., Ltd. According to the agreement, Viva Biotech will cooperate with AlphaMa on innovative drug discovery technology to provide clients with the new generation of AI-based DNA coding compound library (Intelligent DEL, iDEL) screening technology platform for screening tumors and lead compounds for a series of specific targets in the field of neurological, autoimmune and other diseases.

AlphaMa

Viva Biotech Proposed Issue of US\$280 million Guaranteed Convertible Bonds to Support Industrial Chain Integration

On December 18, 2020, Viva Biotech announced the proposed issue of US\$280 million 1.0% guaranteed convertible bonds due 2025. The issuance of convertible bonds provides financial support for the company's industrial chain integration. Viva Biotech intends to apply the proceeds from the Bonds for business development and expansion as well as other working capital and general corporate purposes.

Viva Biotech and Shanghai Biomedical Fund Announce the Cooperation to Jointly Build the Medical Innovation Achievement Transformation Platform

On December 16, 2020, the Shanghai Biomedical Industry Equity Investment Fund, which is approved by the Shanghai Municipal Government and initiated by Shanghai Industrial Investment Holdings was launched in Shanghai. Viva Biotech attended the ceremony and signed the cooperation agreement, to jointly build the Shanghai Biomedical Innovation Achievement Transformation Platform.



Frist from the right: Dr. Chen Mao, Chairman and CEO of Viva Biotech

Viva Biotech Completed the Strategic Integration of Langhua Pharmaceutical Accelerate the Upgrade of the Innovative Drug Industry Service Chain

On November 12, 2020, Viva Biotech completed the integration of 80% of the equity interest of Langhua Pharmaceutical, at the consideration of RMB2,560 million. As a comprehensive pharmaceutical manufacturing enterprise, Langhua Pharmaceutical is committed to becoming the most valuable and creative specialty API supplier and the customer's preferred CDMO partner. This strategic integration is of great strategic significance for Viva Biotech to establish a comprehensive one-stop drug service platform.



Viva Biotech Enters Strategic Collaboration with Biocytogen Jointly Accelerate the Early-stage Drug Discovery

On October 27, 2020, Viva Biotech and Beijing Biocytogen Co., Ltd. announced a strategic collaboration to jointly accelerate the early-stage drug discovery.



Viva Biotech LinkedIn

Business Progress



Xlement Attended 3rd China International Import Exhibition

In November 2020, Xlement, a biotech start-up company who committed to the development of next generation of world-leading Nano-plasmon-resonance (NanoSPR) Biochip micro-test technique, brought two latest equipment, NanoSPR handheld detector and SARS-CoV-2 virus particle antigen detection kit to the 3rd China International Import Exhibition.

Research & Development Progress



VivaVision Biotech's New Drug VVN001 Completed the First Patient Enrollment in the Phase II clinical Trial in US

On December 18, 2020, VivaVision, a leading ophthalmology novel drug developer, announced the company's self-developed new drug for the treatment of xerophthalmia, a new generation of LFA-1 antagonist VVN001, has completed the first patient enrollment in the Phase II clinical trial in the United States.

Arthrosi Therapeutics Released Phase 2 Clinical Data of AR882

On November 7, 2020, Arthrosi Therapeutics, a clinical-stage biopharmaceutical company focused on developing a best-in-class treatment for gout, has completed a Phase 2a clinical trial for company's lead asset, AR882. Results from two clinical studies of AR882 conducted at Australia and New Zealand are being presented in Annual meeting of American College of Rheumatology Convergence 2020. AR882 demonstrated a strong safety profile, favorable pharmacokinetics, pharmacodynamics, and efficacy outcome in healthy volunteers and in gout patients.



Investment Progress

Arthrosi Therapeutics Completed Round C Financing

On October 23, 2020, Arthrosi Therapeutics, a biotech start-up that is dedicated to the R&D of innovative drugs for metabolic diseases, has announced the completion of Round C financing. This round of financing was led by LH Ventures, and several institutions including Viva Biotech, Changrong Capital, HEDA Ventures, Fenghe Group participated, with a total financing amount of more than 100 million RMB. This round of financing will be mainly used for the follow-up clinical research of the company's small molecule drug AR882.



About Viva Biotech

Listing Date
2019.05.09
Price (2020.12.28)
HKD 9.00
52 WK Range
HKD 3.67 – 10.46
Market Cap (2020.12.28)
HKD 17.21B

Viva Biotech's mission is to become a cradle for innovative biotechnology companies around the world. Viva Biotech has developed a scalable business model combining the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers' needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Viva Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model. As of June 30, 2020, Viva Biotech had provided drug discovery services to over 495 biotechnology and pharmaceutical customers worldwide, worked on over 1,300 independent drug targets, delivered over 17,000 protein complex structures and invested/ incubated a total of 56 early stage biotech start-ups.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com.cn

For further information, please contact: Tel: 852-3150 6788
Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com